Today it was reported that a Director at Enzo Biochem (ENZ), Dov Perlysky, exercised options to buy 64,286 ENZ shares at $2.70 a share, for a total transaction value of $173.6K. The options were close to expired and Dov Perlysky retained stocks.
Following this transaction Dov Perlysky’s holding in the company was increased by 12.25% to a total of $2.22 million. In addition to Dov Perlysky, one other ENZ executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Enzo Biochem has an average volume of 276.7K.
The insider sentiment on Enzo Biochem has been positive according to 10 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics.
